enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD
0.6200
-0.0004 (-0.06%)
At close: Mar 28, 2025, 4:00 PM
0.6754
+0.0554 (8.94%)
After-hours: Mar 28, 2025, 4:02 PM EDT
-0.06%
Market Cap 219.20M
Revenue (ttm) n/a
Net Income (ttm) -69.05M
Shares Out 50.98M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,404
Open 0.6599
Previous Close 0.6204
Day's Range 0.6200 - 0.6800
52-Week Range 0.6200 - 0.6800
Beta -0.61
Analysts n/a
Price Target n/a
Earnings Date Mar 13, 2025

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 57
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.